Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Ryan Hasson

EXPLAINED: Can incyte deliver on 447 eps forecasts and pipeline hype - The Real Truth

During a year when healthcare stocks, especially biotechnology, have lagged so deeply behind the overall market, it’s particularly noteworthy that Incyte Corporation (NASDAQ: INCY) has managed to stand out. The stock is up 21.6% year-to-date (YTD), not only outperforming its struggling sector but also surpassing the benchmark S&P 500. 

This strength stems from an impressive second-quarter earnings report and management commentary that have fueled recent momentum. With the stock now edging toward a potential multi-year breakout, the question becomes: can Incyte deliver on its ambitious earnings forecasts and pipeline promises?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.